Diligence memo · auto-generated · as of July 2, 2026

Vitanova Biomedical, Inc.

Vitanova Biomedical, Inc. looks fair against its niche peers and is dormant on financing cadence.

DeprioritizeFinancing has gone silent well past the sector's normal cadence — treat as inactive until outside confirmation of a live operation.

Businessfiled

Vitanova Biomedical, Inc. operates in Biotechnology, based in KERRVILLE.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

Vitanova Biomedical, Inc. has raised $745K in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Pre-Seed (a round under $1.0M).

Largest single filing: $420K on 2018-02-01.

Most recent recorded round closed around 2019-08-26.

Valuation (modeled)modeled

Provath models Vitanova Biomedical, Inc. at approximately $18M (range $173K–$203M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Fair. Modeled value is 1.15× the median modeled value of Pre-Seed Biotechnology companies in 2019–2021 (156 peers) — value vs value, same stage and era. Within the normal band (115% of peer median) for its niche.

Financing rhythm & timingmixed

Historic cadence: a new round about every 4 months.

Last raise 6.8 yr ago; this sector typically re-raises about every 14 months.

Silent for over 3× the sector's normal cadence.

The last round stepped up 1.0× from the prior — scaling.

Comparablesmixed

Capital scale ranks ahead of 14% of Biotechnology peers (4293 compared).

Modeled value ranks above 27% of those peers.

Closest niche peers: Crimson BioPharm Inc., Pinpoint Therapeutics Inc., Transplant Logistics & Informatics Llc, RNAissance AG LLC, Pylum Biosciences, Inc..

Peoplefiled

3 named people on file across officers, directors and signatories.

Risks & flagsmixed

Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.